Mohammed Alhajji, MD
Nephrology · Jonesboro, ARNPI 1962729970
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,688 of the $6,051 with a category attached, or 77.5%. It is spread thinly across 37 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,598, more than ten times the $138 reported in 2019.
Across 208 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vantive US Healthcare LLC$1K
- AstraZeneca$649
- Bayer$484
- Travere Therapeutics, Inc.$431
- Amgen$250
- GSK$247
- plus $3K from 31 others
What the payments were for
- Travel & lodging$1,06218%
- Food & beverage$4,68877%
- Education$3015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vantive US Healthcare LLC | 11 | $1,334 |
| AstraZeneca | 20 | $649 |
| Bayer | 22 | $484 |
| Travere Therapeutics, Inc. | 18 | $431 |
| Amgen(2 entities) | 12 | $250 |
| GSK | 10 | $247 |
| Vifor Pharma, Inc. | 12 | $236 |
| OPKO Pharmaceuticals, LLC | 7 | $197 |
| Otsuka America Pharmaceutical, Inc. | 10 | $197 |
| Boehringer Ingelheim | 12 | $190 |
| Mallinckrodt Hospital Products Inc. | 8 | $181 |
| Fresenius USA Marketing, Inc. | 8 | $159 |
| Heartflow, Inc. | 1 | $152 |
| Ardelyx, Inc. | 5 | $147 |
| Novo Nordisk | 6 | $132 |
| Calliditas Therapeutics US Inc. | 5 | $122 |
| Stryker | 2 | $122 |
| Novartis | 6 | $115 |
| Daiichi Sankyo Inc. | 5 | $88 |
| Teleflex LLC | 2 | $79 |
| Johnson & Johnson | 2 | $57 |
| Akebia Therapeutics Inc | 2 | $47 |
| Aurinia Pharma U.S., Inc. | 2 | $46 |
| Pfizer | 2 | $45 |
| Baxter Healthcare | 1 | $36 |
| Cormedix Inc. | 2 | $34 |
| Radius Health, Inc. | 2 | $33 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Insulet Corporation | 2 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Dexcom, Inc. | 2 | $27 |
| Abiomed | 1 | $27 |
| Nuwellis, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Chronic$1,062
- FFRct$152
- Filspari$129
- Renal - PD$121
- FARXIGA$118
How this compares
$6,051 in reported general payments places this provider in the 80th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 198 | $135,742 |
| VelphoroSucroferric Oxyhydroxide | 33 | $99,025 |
| FarxigaDapagliflozin Propanediol | 98 | $82,195 |
| KerendiaFinerenone | 80 | $75,776 |
| VeltassaPatiromer Calcium Sorbitex | 48 | $38,632 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $21,908 |
| Sevelamer Carbonate | 113 | $15,185 |
| ProsolParenteral Amino Acid 20% No.1 | 64 | $7,416 |
| Calcium Acetate | 61 | $2,697 |
| Losartan Potassium | 352 | $1,986 |
| Torsemide | 54 | $1,824 |
| Nifedipine ErNifedipine | 69 | $1,493 |
| Potassium Citrate ErPotassium Citrate | 24 | $1,065 |
| Cinacalcet Hcl | 36 | $1,065 |
| Calcitriol | 82 | $1,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $190 | $135,742198 claims |
| AstraZenecaFarxiga, Lokelma | $649 | $104,103132 claims |
| Fresenius USA Marketing, Inc.Velphoro | $159 | $99,02533 claims |
| BayerKerendia | $484 | $75,77680 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 85 nephrology providers in Arkansas.
Other nephrology in Jonesboro
- Clinton EdwardsJonesboro$8K
- James MaxwellJonesboro$5K
- Michael MackeyJonesboro$1K
- Gerren HobbyJonesboro$377
- Adam WoodruffJonesboro$358
- Drew HeipleRussellville$236K
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- Shaker QaqishNorth Little Rock$16K
- Michael GerschHot Springs$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.